A PYMNTS Company

Elon Musk’s Neuralink Sends Human Trial Data for Peer Review

By  |  October 5, 2025
Elon Musk’s Neuralink Sends Human Trial Data for Peer Review

Elon Musk’s brain-implant company, Neuralink Corp., has taken a significant step toward scientific transparency by submitting its first human study to a peer-reviewed journal. According to Bloomberg, the company has sent a paper to the New England Journal of Medicine detailing results from three patients who received Neuralink’s brain-computer interface implant.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    Subscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    The paper reportedly includes data on the safety of the procedure, per Bloomberg, and was disclosed by Michael Lawton, president and chief executive of the Barrow Neurological Institute—one of Neuralink’s clinical trial partners. Lawton discussed the submission during a brain-implant conference hosted by the Mount Sinai Health System in New York but declined to share further details about the findings.

    We’d love to be your preferred source for news.

    Please add us to your preferred sources list so our news, data and interviews show up in your feed. Thanks!

    Add as Preferred Source

    Neuralink, which has raised over $1 billion and achieved a $9 billion valuation, is developing brain-computer interfaces that allow users to control devices using neural signals. Despite its high profile, the company has not previously published peer-reviewed data on human trials, making this submission a milestone for both Neuralink and the broader neurotechnology field. According to Bloomberg, other research groups and companies have long shared similar findings publicly, allowing for scientific evaluation and collaboration.

    Lawton also noted that Neuralink’s approach remains focused on patients with significant disabilities, stating during a Bloomberg-moderated panel that the company is still “a long way” from implanting the device in healthy individuals. Neuralink’s president, DJ Seo, said in September that the firm aims to reach that stage by 2030.

    The company has so far implanted devices in 12 individuals, Bloomberg reported. It ultimately hopes to scale to 20,000 implants annually by 2031, potentially generating more than $1 billion in yearly revenue. In addition to its brain-computer interface for digital control, Neuralink is also pursuing technologies to restore vision, interpret speech directly from brain activity, and address neurological disorders such as Parkinson’s disease.

    Source: Bloomberg